dopa decarboxylase inhibitor造句

• New approaches to management include the use of subcutaneous apomorphine, controlled-release preparations of levodopa with a peripheral dopa decarboxylase inhibitor and the continuous intraduodenal administration of levodopa.
• Droxidopa can be coupled with a peripheral aromatic L-amino acid decarboxylase inhibitor ( AAADI ) or DOPA decarboxylase inhibitor ( DDC ) such as carbidopa ( Lodosyn ) to increase central norepinephrine concentrations while minimizing increases of peripheral levels.
• Merck had already synthesized and patented carbidopa, another dopa decarboxylase inhibitor in 1962, and in 1971 Lotti showed that the use of the L-form of carbidopa, further reduced the therapeutic dose of L-DOPA . The combination of L-carbidopa and L-DOPA was marketed under the brand name of Sinemet.
• It was designed to provide a peripherally selective high COMT inhibitory potency and to avoid cell toxicity Opicapone 50 mg is indicated as adjunctive oral therapy to preparations of levodopa + DOPA decarboxylase inhibitors ( DDCIs ) in adult patients with Parkinson s disease ( PD ) and end-of-dose motor fluctuations who cannot be stabilized on those combinations, increasing the bioavailability of levodopa by 24 % vs . entacapone and up to 55 % vs . levodopa formulations alone.